🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Tanawin Nopsopon

Brigham and Women's Hospital

ORCID: 0000-0003-0428-973X

Also affiliated with Chulalongkorn University, Jackson Memorial Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Lung function trajectories in a cohort of patients with moderate‐to‐severe asthma on mepolizumab, omalizumab, or dupilumab”.

Lung function trajectories in a cohort of patients with moderate‐to‐severe asthma on mepolizumab, omalizumab, or dupilumab

Allergy(2024)10.1111/all.16002

N/A

0.406DataRank · unranked

14 citations

Nora A. Barrett, Wanda Phipatanakul, Tanya M. Laidlaw, Scott T. Weiss, Ayobami Akenroye +1 more

Untargeted metabolomic analysis reveals different metabolites associated with response to mepolizumab and omalizumab in asthma

ERJ Open Research(2024)10.1183/23120541.00931-2023

N/A

0.292DataRank · unranked

6 citations

Yulu Chen, Qingwen Chen, Craig E. Wheelock, Scott T. Weiss, Michael J. McGeachie +3 more

Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics

Respiratory Medicine(2024)10.1016/j.rmed.2024.107802

N/A

0.208DataRank · unranked

3 citations

Alyson Brown, Georg Hahn, Matthew A. Rank, Krista F. Huybrechts, Ayobami Akenroye +1 more

Machine learning–derived genetic risk scores identify IL21 as a predictor of response to omalizumab and dupilumab in asthma

Frontiers in Allergy(2025)10.3389/falgy.2025.1670783

N/A

0.165DataRank · unranked

2 citations

Chengyue Zhang, Tanawin Nopsopon, S. Kalra, Scott T. Weiss, Matthew Moll +1 more

Patients with Higher Exacerbation Burden and Eosinophil Counts are More Likely to Require Multiple Biologics for Asthma Control

Journal of Asthma and Allergy(2025)10.2147/jaa.s543815

N/A

0DataRank · unranked

1 citations

Tanawin Nopsopon, Ayobami Akenroye, Alyson Brown

Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis

The Journal of Allergy and Clinical Immunology In Practice(2023)10.1016/j.jaip.2022.12.046

N/A

0DataRank · unranked

42 citations

Tanawin Nopsopon, Ayobami Akenroye, Ming‐Li Chen

Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level

Scientific Reports(2024)10.1038/s41598-024-60864-3

N/A

0DataRank · unranked

12 citations

Tanawin Nopsopon, Jonathan Hacker, Tanya M. Laidlaw, Ayobami Akenroye

Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis

Journal of Allergy and Clinical Immunology(2022)10.1016/j.jaci.2022.11.021

N/A

0DataRank · unranked

72 citations

Grace Lassiter, Ming‐Li Chen, G. Caleb Alexander, Corinne Keet, Hwanhee Hong +2 more